

Faculty Appointment**2014 – Present Assistant Professor, University of Colorado School of Medicine**

Division of Hematology, Hematologic Malignancies and Stem Cell Transplant

Clinical Director of Lymphoma Services

Education

2013 - 2014 Fellowship	Stanford University Hospital and Clinics Division of Blood and Marrow Transplantation	Stanford, CA
2010 - 2013 Fellowship	East Carolina University ECU; Brody School of Medicine Department of Hematology and Oncology, Vidant Medical Center	Greenville, NC
2007 - 2010 Residency	East Carolina University Brody School of Medicine Department of Internal Medicine, Vidant Medical Center	Greenville, NC
1999 - 2004 Medical School	K.J. Somaiya Medical College MBBS - Bachelor of Medicine and Bachelor of Surgery	Mumbai, India

License and Certifications

Hematology	ABIM Certified (2013)
Medical Oncology	ABIM Certified (2013)
American Board of Internal Medicine	ABIM Certified (2010)
ECFMG	Certified (2007)
MBBS (India)	Certified (2005)
California Medical License	6/2013-10/2014
Colorado Medical License	8/2014-Present

Awards and Scholarships

2018 -19	LRF Scholar for the lymphoma research clinical mentoring program (LCRMP)
2017	Featured MD in the annual impact journal <i>Momentum</i>
2016	Featured MD in the C3 (Collaborating to Conquer Cancer) Magazine
2015	Leadership and Service award; Division of Hematology, University of Colorado
2011	Outstanding presenter of the year in the trainee category at Research Day, ECU
2009 - 2010	Eugene Furth, MD award for Outstanding Senior Resident in Medicine, ECU
2009 - 2010	Outstanding resident in Ambulatory General Medicine, ECU
2009 - 2010	Sir William Osler award for Outstanding Cardiology Resident, ECU
2007 - 2008	Medicine Intern of the year, ECU
2007 - 2008	Hematology-Oncology Intern of the year, ECU
1999 - 2004	Sir J.R.D. Tata Scholarship (partly funded medical school)
2004	Gold Medal State award in Pediatrics, Mumbai University, India
1999 – 2004	Secured Distinction in Pharmacology, Microbiology, General Surgery and Ophthalmology

Abstracts and Presentations

- 2018 **Polatuzumab vedotin with bendamustine and rituximab/ obinutuzumab in relapsed/refractory DLBCL: Updates results of a Phase Ib/II Study**
LSehn, MKamdar, Aherrera, GKU, MMatasar
American society of clinical oncology- Oral Abstract 7507
ASH 2018- Abstract 1683
- 2018 **Addition of rituximab to high-dose methotrexate regimens improves complete response rates and median overall survival in non-germinal center primary CNS lymphoma**
NMistry, MKamdar, DNeY
ASH 2018- Abstract 4217
- 2018 **Outcomes of follicular lymphoma patients treated with frontline bendamustine rituximab: impact of histologic grade and early progression on overall survival.**
AWinter, LNastoupil, MKamdar, Bhill
ASH 2018- Abstract 4146
- 2018 **Chronic graft versus host disease burden and relapse rates are lower with comparable overall survival and graft versus host disease free, relapse free survival following adult umbilical cord transplantation.**
PSharma, MKamdar, JGutman
ASH 2018- Abstract 4660
- 2018 **Baseline PET-CT functional parameters to identify low-grade versus grade 3A FL**
AMajor, AHammes, RMorgan, MKamdar
American society of clinical oncology-Abstract e19541
- 2018 **Risks and types of secondary primary malignancies in DLBCL survivors changes over time based on stage at diagnosis**
AMajor, DSmith, DGhosh, RRabinovitch, MKamdar
American Society of clinical oncology- Abstract e19540
- 2018 **Cardiac assessment within 5 years of lymphoma treatment can detect patients with high risk of cardiotoxicity and undiagnosed coronary artery disease**
NMistry, DSmith, LKondapalli, DGhosh, MKamdar
American society of clinical oncology- Abstract e19562
- 2018 **A phase 1 study of ALX148, a CD47 blocker, alone and in combination with antibodies in patients with advanced malignancy and non-hodgkin Lymphoma**
NLakhani, MKamdar, WMessersmith
American society of clinical oncology- Poster Abstract 3068

- 2018 **Multi-center retrospective study evaluating outcomes of grade 3 A follicular lymphoma**
KGreene, TPhillips, ADanilov, MKamdar, DStephens
American society of clinical oncology- Poster Abstract 7551
- 2018 **Long term follow up of S1106: Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma**
MKamdar, RChen, JFriedberg, SSmith
LRF Mantle cell lymphoma workshop- Session VI MCL
ASH 2018- Abstract Poster 1593
- 2018 **Phase 1 study of Molibresib, a selective bromodomain and extra terminal protein inhibitor: Results from part 1 of Phase I/II open label single agent study in patients with acute myeloid leukemia**
MDickinson, MKamdar, ADhar
ASH 2018- Abstract 1682
- 2017 **Addition of Polatuzumab vedotin to bendamustine and rituximab improves outcomes in transplant ineligible patients with relapsed refractory diffuse large B cell lymphoma versus BR alone: results from a randomized phase 2 study**
LSehn, MKamdar, CFlowers
ASH 2017- Abstract 2821
- 2017 **Administration of Plerixafor for peripheral blood CD34+ stem cell content of less than $30 \times 10^6/L$ for autologous stem cell mobilization leads to decreased apheresis days and increased total yield**
MKamdar, CSmith
EBMT- Abstract A091
- 2017 **Polatuzumab Vedotin combined with bendamustine and rituximab or obinutuzumab in patients with relapsed or refractory follicular lymphoma or diffuse large b cell lymphoma**
AHerrera, M,Matasar,MKamdar, LSehn
American Society of Hematology- Abstract 4194
14th ICML Conference- Lugano- Abstract 284
EHA 2017 (Updated results) – Selected for Oral presentation- Abstract S468
- 2016 **Checkpoint blockade for treatment of relapsed lymphoma following allogeneic Hematopoietic cell transplant: use may be complicated by onset of severe acute graft versus host disease**
BHaverkos, MKamdar, SDevine
American Society of Hematology- Abstract 1163
- 2016 **Presenting characteristics and Treatment selection for elderly patients with**

Classical Hodgkin Lymphoma

MWJackson, MKamdar, RRabinovitch

Pan Pacific Lymphoma conference (Accepted for poster Presentation)

- 2016 **Post transplant diffuse large B cell lymphoma with non germinal center B-cell subtype frequently lacks programmed cell death ligand (PD-L1) overexpression which may influence overall outcomes**
ZNooruddin, MKamdar
ASH meeting on Lymphoma- Abstract 90, ASH 2016- Abstract 3054
- 2016 **Final results of IHC analyses and Prognostic factors in post transplant lymphoproliferative disorders after solid organ transplantation: A single center Experience:** ZNooruddin, MKamdar
European Hematology Association- Abstract EHA-3164
- 2016 **Single Institution Retrospective Review of patients with Primary CNS Lymphoma**
AJohnson, MKamdar, DNey
American Society of Clinical Oncology- Abstract 165552
- 2015 **IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A single center experience**
ZNooruddin, MKamdar
American Society of Hematology – Abstract 1443
- 2014 **Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained disease response and promising donor immune modulation:** CRyan, MKamdar, DMiklos
American Society of Hematology – Abstract 1186
- 2013 **An internist's perspective of acquired hemophilia**
American College of Physicians, NC Chapter
- 2013 **KRAS gene mutation status in lung cancer affects sensitivity to pemetrexed:** A retrospective analysis- J Clin Oncol 31,2013 (suppl;abstr e19154)
Author(s): Manali K Kamdar, Teresa Parent, Paul R Walker
- 2012 **Retrospective review of patients afflicted with TTP in East Carolina:** MKamdar, DLiles
American Society of Hematology - Abstract 2200
- 2012 **Phase II Trial with daily Pulse Interleukin-2 therapy in patients with Acute Myeloid Leukemia:** PWalker, MKamdar, AAsch
J Clin Oncol 30, 2012 (suppl; abstr e17008)

- 2011 **Sudden cardiac death in the sickle cell patient population:** MKamdar, DLiles
American Society of Hematology - Abstract 1061
- 2010 **A retrospective review to evaluate the safety and survival of treatment of adults with newly diagnosed Glioblastoma Multiforme with surgery, Gliadel Wafers, radiation and concurrent Temozolomide followed by adjuvant Temozolomide:** MKamdar, DThompson
American Association of Neurosurgeons Society - Abstract 64831

Grants and Funding

- Active** Recipient of seed grant support from the Morton and Sandra Saffer Endowment in Cancer Research
- Active** Pilot research fund from Patrick Riley in cancer research

Current Research

Investigator Initiated Clinical Trials: Lead PI

- 1) Polatuzumab plus Bendamustine plus Rituximab as salvage therapy prior to autologous stem cell transplant for patients with relapsed or primary refractory diffuse large B-cell lymphoma (Concept and protocol accepted; Regulatory process ongoing)
- 2) Ublituximab as initial therapy for treatment-naïve follicular and marginal zone lymphoma with response-driven addition of umbralisib for suboptimal response (Concept accepted by TG therapeutics; Protocol in review)

Industry Sponsored Clinical Trials:

Ongoing Trials

- 1) A Study of Idasanutlin in Combination With venetoclax and Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants (Lead PI)
- 2) Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (Institutional and CO-PI)
- 3) Study of AZD 5991 in relapsed or refractory haematologic malignancies

Completed Trials

- 1) A Phase IB/II Study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in relapsed or refractory follicular or diffuse large B cell Lymphoma (Institutional PI)
- 2) A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, ACP-196 in Combination With Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL (Institutional PI)
- 3) A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers (Co-PI)
- 4) A study to determine dose, safety, and efficacy of Durvalumab as Monotherapy and in Combination therapy in subjects with Lymphoma or Chronic lymphocytic leukemia (Institutional PI)
- 5) A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies (Institutional PI)

Co-operative group Clinical Trials (SWOG)

- 1) A Randomized double-blind phase III study of Ibrutinib versus placebo during and following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b cell lymphoma of the activated b-cell subtype (Institutional PI) (Closed)
- 2) Obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy in treating patients with relapsed refractory Grade I-IIa follicular lymphoma (Institutional PI) (Closed)

Publications

2018 Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis

AMajor, **MKamdar**, RRabinovitch

Leukemia Lymphoma: 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1522435. [Epub ahead of print]

2018 Positron Emission Tomography-based Analysis Can Accurately Predict Bone Marrow Involvement With Mantle Cell Lymphoma.

Morgan R, **Kamdar M**

[Clin Lymphoma Myeloma Leuk](#). 2018 Jul 4. pii: S2152-2650(18)30393-8. doi: 10.1016/j.clml.2018.06.024. [Epub ahead of print]

2018 Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder

Major A, **Kamdar M**

Curr Treat Options Oncol. 2018 May 24;19(7):33. doi: 10.1007/s11864-018-0549-6

2018 Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison

Sharma P, Pollyea D, Smith CA, Purev E, **Kamdar M**, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA

2017 PD-1 Blockade in mediastinal gray zone lymphoma

Melani C, Major A, Wilson W, **Kamdar MK**

New England Journal of Medicine 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767

2017 PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, **Kamdar MK**, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM
Blood. 2017 May 3. pii: blood-2017-01-761346. doi: 10.1182/blood-2017-01-761346 ((Epub ahead of print))

2017 Marginal Zone Lymphoma: no longer just a side kick

Kamdar MK, Smith S

Journal of clinical Oncology/2017 Apr 27;JCO2017722835. doi: 10.1200/JCO.2017.72.2835

2017 Secondary CNS Involvement of ALK-Negative Anaplastic Large Cell Lymphoma.

Major A, Pan Z, **Kamdar MK**

Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24733. [Epub ahead of print]

2016 Improved Survival with Combined Modality Therapy in the Modern Era for Primary Mediastinal B-Cell Lymphoma

Jackson MW, Rusthoven CG, **Kamdar MK**, Rabinovitch R

Am J Hematol. 2016 Feb 6. doi: 10.1002/ajh.24325

2015 Improved Survival with Radiotherapy in Stage I-II Primary Mediastinal B-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis

Jackson MW, Rusthoven CG, **Kamdar MK**, Rabinovitch R
International Journal of Radiation Oncology*Biography*Physics. 2015 Sep 25.
doi:10.1016/j.ijrobp.2015.09.017

Book Chapter(s) and other media/press

- 2018 Update on Mantle Cell Lymphoma : LRF & CancerCare Teleconference
https://www.cancerca.org/connect_workshops/692-update_mantle_cell_lymphoma_2018-10-26
- 2017 CLL society newsletter, *THE CLL tribune*
<http://cllsociety.org/2017/09/prognostic-factors-cll/>
- 2017 Oncology times: commentary on CheckMate-205 trial
http://journals.lww.com/oncology-times/Fulltext/2017/08100/Longer_Nivolumab_Response_Reported_in_Hodgkin.3.aspx
- 2017 Radio interview: Importance of genetic testing in CLL patients
- 2017 Featured MD in Colorado Cancer blogs
<http://www.coloradocancerblogs.org/nejm-case-reports-show-promise-cancer-immunotherapy-treat-rare-lymphoma/>
- 2014 Chapters: 1. Sirolimus 2. HLA
Publication: Guide to clinical hematopoietic cell grafting (The Stanford Red Book)
Supervisor: Dr. Jonathan Benjamin

Journal Reviewer

- 2019 American Journal of hematology
2017-2018 Journal of Clinical Oncology
2017 Journal of Clinical Leukemia, Lymphoma and Myeloma
2015 Journal of the National Comprehensive Cancer Network

Editorial Responsibilities

- 2018 Editorial Board, *Clinical Lymphoma, Myeloma and Leukemia*

Lectures (On campus)

- | | | |
|------|----------------------|---|
| 2019 | State of CLL in 2019 | BMT grand rounds and Hem Onc grand rounds |
| 2019 | Transformed Lymphoma | BMT Grand rounds and Hem Onc Grand Rounds |
| 2018 | How I treat CLL | Hem Onc grand rounds |

2018	ASH update in B cell lymphomas	Hem Onc grand rounds
2018	PD-1-PD-L1 checkpoint blockade in lymphomas	BMT grand rounds
2018	Lymphoma: Overview	Breakfast BIC talk
2018	Clinical Trials in Lymphoma	HCTU Lunch Talk
2017	Lymphomas: update on radiation therapy use	Rad/Onc grand rounds
2017	Updates in Mantle cell lymphoma	BMT grand rounds
2017	Hodgkin Lymphoma in 2017: Updates	Hem/Onc Grand Rounds
2017	Update on Marginal Zone Lymphoma	BMT grand rounds, Hem/Onc gr Rnds
2016	Lymphomas: Overview and Updates	Oncology Boot Camp
2016	Hodgkin Lymphoma in 2016	Rad/Onc Grand Rounds
2016	Hodgkin Lymphoma	Hem/Onc Grand Rounds
2016	Updates in Lymphomas	Bone marrow infusion center breakfast talk
2016	Roadmap forward in DLBCL	Research and Innovation Conference
2015	ASH 2015 Update (Lymphomas)	Hem/Onc Fellows Conference
2015	Lymphomas (DLBCL,FL,MCL, Burkitt L)	BMT Grand Rounds
2015	Review of Lymphomas	Radiation Oncology Grand Rounds
2015	Overview of Lymphoid malignancies	Clinical Trials Team "Lunch and Learn"
2015	Lymphomas (DLBCL,FL)	Hem/Onc Fellows Conference

Lectures (Regional)

2018	Ask the Doctor: B-cell lymphomas	Lymphoma Research Foundation
2018	Echelon-1 overview(Pharma)	Oncology Nursing Association, Denver
2017	Ask the Doctor: Updates in Lymphoma	Lymphoma Research Foundation
2017	Highlights of ASH: B cell Lymphoma	Denver Metro Region
2016	Brentuximab in Lymphomas (Pharma)	Callaway Young Regional Cancer Center
2016	Brentuximab in Lymphomas (Pharma)	Cheyenne Regional Cancer Center
2016	Lymphoma Overview and Updates:	Celgene Educational Denver Region talk
2016	Ask the Doctor: Updates in B cell Lymphoma	Lymphoma Research Foundation
2016	Overview of Brentuximab(Pharma)	Oncology Nursing Association, Denver
2016	ASH Review: Update on Lymphoma	UC Health Annual ASH Update CO Springs

Lectures (National and International) (Invited speaker)

2019	Immunotherapy in lymphoma	Plenary Session: Arizona lymphoma workshop
2019	DLBCL/Burkitt lymphoma	Arizona lymphoma workshop (LRF)
2018	Marginal Zone lymphoma	North American Educational Forum (LRF)
2018	Best of ASH: Update in indolent B cell lymphomas	41 st Mumbai hematology Meeting
2018	PD1/PDL1 checkpoint blockade in lymphomas	41 st Mumbai Hematology Meeting
2018	Mantle cell lymphoma- update	Arizona lymphoma workshop LRF
2017	Mantle cell lymphoma guidelines	AstraZeneca national educational program
2017	ASH 2016: Highlights in B cell lymphoma,	University of Oklahoma, OKC
2016	ASH 2015: Highlights in lymphoid malignancy	East Carolina University, NC

Reviews/Projects/Academic Activities

2017 Co-Developed an active and running lymphoma database

2017 Junior Faculty Survival Skills training

2017 Junior Faculty Mentoring Program (JUMP)

2015 Chair weekly tumor board for the Division of Hematology

2016 Co-developed protocol for tissue banking of lymphoma patients

2015 Co-Developed Institutional Guidelines for treating Lymphomas

2015 Co-developed a cardio oncology program with cardiologist Dr Konadapalli at the U of CO

(Manuscript in progress) Outcome Analysis in patients with Post transplant lymphoproliferative disorder DLBCL type after solid tumor transplant based on IHC analysis

(Manuscript in progress) Single Institutional review of CNS lymphomas diagnosed after 1999: Prognostic factors and Outcome analyses.

Appointments and Committees

2017-2019	Hematology/Oncology fellowship recruitment committee	
2017-19	NCCN guidelines panel member for CLL/SLL/Hairy cell leukemia committee	
2016	Practical medical education and science: Associate editor	
2015	Southwest Oncology Group, Lymphoma Committee Member	
2014-present	Clinical Director of Lymphoma Services	UC Denver/Division of Hematology
2012 – 2013	Chief Fellow Dept. of Hematology and Oncology	ECU
2008 – 2010	Residency Recruitment Committee	ECU

Professional Memberships/Societies

American Society for Blood and Marrow Transplantation
 American Society of Hematology
 American Society of Clinical Oncology
 European Hematology Association

Manali Kamdar, MD

720-848-0752 (O); 720-848-1786 (F)

Mail Stop F754 1665 Aurora Court Aurora, Colorado 80045

manali.kamdar@ucdenver.edu

Mentees

Zohra Nooruddin, MD- past Hematology/Oncology fellow now assistant professor at San Antonio VA

Ajay Major, MD, MBA – Resident in Internal Medicine (Matched at the University of Chicago for Hem/Onc Fellowship)

Neelam Mistry, MD- Resident in Internal Medicine (Chief Resident 2019-2020)